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Abstract:  102 
Most psychopathological disorders develop in adolescence. The biological 103 
basis for this development is poorly understood. To enhance diagnostic 104 
characterisation, and develop improved targeted interventions, it is critical to 105 
identify behavioural symptom groups that share neural substrates. We ran 106 
analyses to find relations between behavioral symptoms, and neuroimaging 107 
measures of brain structure and function in adolescence. We found two 108 
symptom groups, consisting of anxiety/depression and executive dysfunction 109 
symptoms respectively, which correlated with distinct sets of brain regions 110 
and inter-regional connections, measured by structural and functional 111 
neuroimaging modalities. We found that the neural correlates of these 112 
symptom groups were present before behavioural symptoms had developed. 113 
These neural correlates showed case-control differences in corresponding 114 
psychiatric disorders, depression and ADHD, in independent clinical samples. 115 
By characterising behavioral symptom groups based on shared neural 116 
mechanisms, our results provide a framework for developing a classification 117 
system for psychiatric illness, which is based on quantitative 118 
neurobehavioural measures. 119 
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Adolescence and its transition toward young adulthood is a critical period for 125 
the development of psychiatric illness with half of the lifetime psychopathological 126 
burden emerging by the mid-teens, and 75% by the mid-20s1. It coincides with major 127 
structural changes in grey and white matter2 that are particularly pronounced in the 128 
limbic system and the prefrontal cortex3. Cognitive and (other) behavioural 129 
maturation reflects this brain-wide developmental process4. As psychopathological 130 
symptoms during adolescent brain re-organization are often unspecific, and in many 131 
cases reversible, it has been difficult to unambiguously identify early markers for 132 
sustained mental illness. Thus, most patients present during adulthood, often at a 133 
point when severe psychopathology has developed, which gravely impairs their daily 134 
functioning. Presentation at this advanced stage increases individual suffering and 135 
renders therapeutic interventions more difficult. 136 
         Currently, both adolescent and adult psychiatric diagnoses are made on the 137 
basis of combinations of behavioural symptoms that - whilst reflecting the 138 
psychopathological experience of generations of clinicians and patients - are not 139 
necessarily related to homogeneous pathophysiological or etiological processes. 140 
This results in biological heterogeneity within diagnostic entities5 , high rates of 141 
comorbidity between diagnoses6,7, and ill-defined targets for drug development. This 142 
is particularly relevant in adolescence, where there is evidence to suggest that 143 
psychiatric illness is more dimensional and less categorical than adult 144 
psychopathology. Neuroimaging methods offer the opportunity to identify the 145 
biological mechanisms underpinning mental illness, without recourse to these 146 
categorisations8,9.  147 
One of the challenges in breaking up diagnostic borders in favour of more 148 
homogenous clusters of symptoms sharing common neural mechanisms, is that 149 
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biological and behavioral data need to be combined in a meaningful way. A suitable 150 
method for this purpose is canonical correlation analysis (CCA), which is formulated 151 
to maximize the correlation between variables in two views of a dataset. This 152 
technique has previously been used to link complex behavioural datasets with 153 
functional brain networks10. However, CCA has a number of limitations: It cannot be 154 
applied to data with more features than samples, results are difficult to interpret 155 
owing to a lack of localizability, and it is only possible to find relations between two 156 
sets of variables. The first two of these issues can be addressed using sparse 157 
canonical correlation analysis (sCCA)11,12, which has been used to find modes of 158 
shared variation between resting state functional connectivity MRI, and behavioral 159 
measures in adolescents and young adults12. However, this approach is still limited 160 
in that it is only possible to identify relations between psychiatric symptoms and one 161 
kind of biological measure at a time. We further enhanced sCCA by formulating a 162 
constrained form of multiple canonical correlation analysis, which maximizes the 163 
correlation between psychiatric symptoms, and several different neuroimaging 164 
modalities simultaneously13, before combining them in a linear regression model; we 165 
term this approach sparse multiple canonical correlation analysis regression 166 
(msCCA-regression). 167 
         We investigated whether symptoms contributing to DSMV/ICD10 diagnoses 168 
can be reconfigured to identify ‘neurobehavioral’ symptom groups that best represent 169 
specific underlying dysfunctional brain networks in adolescence. Here, we used a 170 
data driven approach applied to a large general population neuroimaging sample to 171 
investigate direct relations between neuroimaging measures of brain structure and 172 
function, yet without immediate recourse to diagnostic psychiatric categories. 173 
Following this, we sought to determine whether the regions we found to be related to 174 
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psychiatric symptoms in adolescence were associated with fully-blown clinical 175 
psychopathology in several independent clinical samples. Overall, this multi-step 176 
approach enabled us to identify brain correlates of psychopathology in adolescence, 177 
probe their predictive value in the critical period between age 14 and age 19, and 178 
characterize these brain correlates against the development of full-blown 179 
psychopathology.  180 
 181 
 182 
Results 183 
We used msCCA-regression (please see the methods section under the sub-184 
heading: Multiple Sparse Canonical Correlation Analysis Regression) to link 185 
participant responses to the Development and Well Being Assessment (DAWBA), a 186 
structured interview for psychiatric DSMV/ICD-10 diagnoses14 (Supplementary Table 187 
1), with voxel-based morphometry (VBM)15 measures of grey matter volume, 188 
fractional anisotropy (FA) along major white matter tracts using tract-based spatial 189 
statistics (TBSS)16, and functional connectivity between different brain regions, 190 
mapped from resting state (rs-fMRI) scans17. T1 and DTI data were pre-processed 191 
using voxel-wise VBM18 and TBSS19  methods respectively, as these procedures 192 
have been extensively studied and applied to real data. We mapped inter-regional 193 
rs-fcMRI connections across the brain using nodal maps defined by Miller et al17, 194 
reasons for our pre-processing and analysis choices are detailed in the methods 195 
section of the paper under the sub-heading: Different Neuroimaging Pre-processing 196 
Strategies. We investigated ninety DAWBA items (symptoms) related to a broad 197 
range of psychiatric disorders, including affective and anxiety symptoms, attention 198 
deficit/hyperactivity and conduct symptoms, as well as substance use, eating 199 
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disorders, and symptoms of psychosis (Supplementary Table 1)14. This analysis was 200 
carried out on the general population IMAGEN sample, on participants of age 19. 201 
Following an in-depth QC (see methods under the sub-heading: IMAGEN analysis), 202 
data for n = 666 participants was available at age 19.  203 
To avoid overestimating the variance shared between psychiatric symptoms, 204 
and the neuroimaging modalities analysed (overfitting), we used a train/test analysis 205 
design, which allows us to estimate effect sizes in an unbiased way. Using a test set 206 
also allowed us to carry out further characterization of the data, without running into 207 
circularity problems. We carried out model selection in a training dataset of 70% of 208 
the data (n=467), and model validation in the testing dataset of the remaining 30% 209 
(n=199). To enhance stability we resampled the data and retained only variables that 210 
contributed to the model in 90% of resamples (see methods under the sub-heading: 211 
Stability Selection, and Supplementary Figure 1)21. Demographic information on the 212 
full sample, training and testing sets is given in Supplementary Figure 2. The 213 
msCCA-regression procedure we used in this investigation is designed to maximise 214 
associations between variable-sets. For this reason, all msCCA-regression 215 
significance values reported in the text are one-sided. 216 
 217 
Using msCCA-regression, we found a significant relation between a subset of six 218 
DAWBA symptoms (see Figure 1), and VBM, TBSS and rs-fMRI measures 219 
(r=0.59(465), p<0.001). The behavioural correlates derived from DAWBA covered 220 
symptoms linked to feelings of depression, anxiety and somatic problems, as well as 221 
temper and attentional problems (Figure 1). The model was also significant when 222 
applied to the test dataset (r=0.23(197), p<0.001, 95% CIs=0.13, ∞) (Figure 1), 223 
explaining 5.30% of the variance between psychiatric symptoms and the brain. Brain 224 
 9
correlates derived from VBM, TBSS and rs-fcMRI measures were associated with 225 
this anxiety/depression symptom group with correlation values of: r=0.16(197), 226 
p=0.017, 95% CIs=0.040, ∞; r =0.14(197), p=0.040, 95% CIs=0.037, ∞ and 227 
r=0.15(197), p=0.029, 95% CIs=0.041, ∞ respectively (with all p-values FWE-228 
corrected for multiple comparisons, see methods under the sub-heading: Analysis 229 
Design,  and Supplementary Figure 3).  230 
VBM, TBSS and rs-fcMRI modalities all showed an individually significant 231 
relation to psychopathology. We carried out further localization analyses in each 232 
modality to identify brain regions that showed an individually significant relation to 233 
psychopathology (see methods under the sub-heading: Additional Analyses to 234 
Localise Effects). In this localization analysis, we identified one gray matter cluster in 235 
the right inferior temporal gyrus (r=0.16(197), p=0.032 FWE corrected, 95% 236 
CIs=0.041, ∞), and a single cluster of decreased fractional anisotropy in the genu of 237 
the corpus callosum (r = 0.16(197), p=0.031 FWE corrected, 95% CIs=0.041, ∞). 238 
Both of these brain regions have been among those exhibiting the largest differences 239 
between healthy controls and patients with depression, in recent large, well-powered 240 
meta-analyses22,23. Further, we found an increase in functional connectivity between 241 
the default mode network, and the cerebellum (r=0.15(197), p=0.041 FWE corrected, 242 
95% CIs=0.037, ∞); the default mode network has been implicated in several 243 
different psychiatric disorders, but depression in particular, with recent research 244 
showing that connectivity between the cerebellum and the default mode network is 245 
altered in patients with depression24. Information on the full set of regions found to be 246 
associated with psychiatric symptoms can be found in Supplementary Tables 2 and 247 
3 and Supplementary Figures 4 and 5. 248 
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We then removed the effects of the first canonical relation and investigated 249 
the presence of a second dimension of shared variance between symptoms and the 250 
brain (see methods under the sub-heading: Finding Multiple Modes of 251 
Variation).  Here, we identified another behavioral correlate consisting of five items 252 
from the DAWBA, including: problems with attention, fidgeting, rapidly changing 253 
moods and (lack of) conscientiousness that was significantly associated with the 254 
neuroimaging modalities (r=0.46(465), p=0.004). The test sample correlation is 255 
significant at (r=0.19(197), p=0.002, 95% CIs=0.087, ∞), explaining 3.61% of the 256 
variance between psychiatric symptoms and the brain. Brain correlates derived from 257 
VBM, TBSS and rs-fcMRI measures were associated with the executive dysfunction 258 
symptom group with correlation values of r=0.19(197), p=0.012, 95% CIs=0.079, ∞; 259 
r=0.070(197), p=0.21, 95% CIs=-0.029, ∞ and r=0.020(197), p=0.58, 95% CIs=-260 
0.090, ∞ respectively. These results are displayed in Figure 2. 261 
 262 
As the VBM modality was the only modality in this second canonical relation 263 
to show an individually significant relation to psychopathology, we only carried out a 264 
localization analysis for VBM data in this modality; we found that executive 265 
dysfunction symptoms correlated with a single grey matter cluster in the right middle 266 
temporal gyrus (r = 0.16(197), p = 0.024 FWE corrected, 95% CIs=0.049), an area 267 
that has previously been shown to be associated with ADHD symptomology25. 268 
Information on the full set of regions found to be associated with psychiatric 269 
symptoms can be found in Supplementary Tables 4 and 5 and Supplementary 270 
Figures 4 and 5. Associations between canonical anxiety/depression and executive 271 
dysfunction canonical correlates are given in Supplementary Table 6. Our results 272 
were robust to different rs-fcMRI atlas choices, as shown by repeated analyses using 273 
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a different nodal definition20, which generated similar results (Supplementary Figure 274 
6). 275 
 276 
 277 
Hypothesis Driven Analysis 278 
To determine if the canonical symptom groups identified in our data-driven analysis 279 
show a stronger relation to neuroimaging measures than existing means of 280 
organizing psychiatric symptoms, we carried out a hypothesis driven analysis using 281 
internalizing and externalizing symptoms, which are often used in adolescent 282 
psychiatric diagnostics. We tested whether the canonical symptom groups identified 283 
with msCCA-regression were able to explain more variance than this widely used 284 
model of illness (see methods under the sub heading: Hypothesis Driven Analysis)26. 285 
We term these pre-defined symptom groups as DAWBA-internalising and DAWBA-286 
externalising. We found that the correlation of the DAWBA-internalising dimension of 287 
psychopathology with neuroimaging measures only shows trend-level significance in 288 
the test set (r=0.12(197), p=0.060, 95% CIs=-0.02, ∞) and explains 1.9% of variance. 289 
Similarly, DAWBA-externalising dimensions of psychiatric illness correlated with 290 
neuroimaging measures at (r=0.040(197), p=0.28, 95% CIs=-0.095, ∞) in the test 291 
set, explaining 0.16% of the variance (Supplementary Figure 7). We then used a 292 
modified version of Dunn and Clarke’s z27,28 to test directly whether the association 293 
of the canonical symptom groups with the brain was significantly stronger than their 294 
pre-defined analogues. While the symptom-brain correlation of the executive-295 
dysfunction symptom group was indeed significantly stronger than that of the 296 
DAWBA-externalizing symptom group (Z=1.95(196), p = 0.029), we did not find 297 
evidence that the strength of the association between the anxiety/depression 298 
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symptom group and the brain was significantly larger than that of the DAWBA-299 
internalizing group (Z=0.92(196), p = 0.18).  300 
 301 
Longitudinal Analysis 302 
We carried out the initial cross-sectional analysis relating psychiatric symptoms to 303 
brain at age 19, as most psychopathological symptoms will have become manifest 304 
by this age. To investigate how adolescent brain development relates to the 305 
development of psychopathological symptoms, we analyzed data from the same 306 
participants at age 14 years. First, we repeated the cross-sectional msCCA-307 
regression analysis using VBM and TBSS (rsfMRI data was not available at age 14). 308 
We found a non-significant, trend level association between symptoms and 309 
neuroimaging measures of r = 0.42(410), p = 0.11 in the training set. We found 310 
similarly non-significant results in the testing set (r = 0.10(180), p = 0.090, 95% CIs=-311 
0.017,∞). The results of these analyses are displayed in Supplementary Figure 8.  312 
There is previous evidence to suggest that neuroimaging measures precede the 313 
development of psychiatric symptoms in adolescence29. We tested whether that was 314 
the case with the canonical symptom groups established in the present study by 315 
extracting the TBSS and VBM regions discovered at age 19 and using them as 316 
regions of interest at age 14. In order to obtain unbiased estimates of effect, we 317 
looked for associations in the test sample. After a conservative quality control 318 
procedure (see methods under the sub-headings: Longitudinal Analysis), n = 182 319 
participants were available for analysis at this time-point. Our data did not show any 320 
evidence of an association between anxiety/depression brain correlates and 321 
anxiety/depression symptoms at 14 years r=0.020(180), p=0.40, 95% CIs=-0.10, ∞. 322 
However, the brain correlates taken from data at age 14, were predictive of 323 
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symptoms at age 19 r=0.14(180), p=0.023, 95% CIs=0.022, ∞. These results are 324 
shown in figure 3. The difference in correlation between brain correlates at age 14 325 
years with anxiety/depression symptoms at 14 years and 19 years was also 326 
significant, testing for a difference in association using a modified version of Dunn 327 
and Clarke’s Z (Z=1.74(179), p=0.041)28. We did not find evidence of an association 328 
between brain correlates and symptoms of executive dysfunction at age 14 years 329 
(r=0.030(180), p=0.41, 95% CIs=-0.093, ∞). Prediction of symptoms at 19 years 330 
showed a trend towards significance (r=0.11(180), p=0.065, 95% CIs =-0.010, ∞).  331 
  332 
  333 
 334 
 335 
Clinical Characterization 336 
We investigated whether the canonical correlates of psychopathology we identified in 337 
a general population adolescent sample are correlated with fully developed 338 
psychiatric illnesses. In these analyses, we looked for case-control differences in the 339 
anxiety/depression and executive dysfunction canonical correlates, across four 340 
common psychiatric illnesses in several independent clinical samples. We carried out 341 
these analyses using VBM data alone, as this was the only data modality that 342 
showed an individually significant association with both symptom groups. Clinical 343 
and demographic information associated with the different clinical samples is 344 
displayed in Supplementary Figure 9 and Supplementary tables 7-9. Extensive 345 
information on quality control and data exclusion criteria for these clinical samples is 346 
given in the methods section of this paper following the sub-heading: Clinical 347 
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Analyses. In assessing this data, we were looking for a directional effect, we 348 
therefore report significance levels resulting from one-tailed tests in this section of 349 
the paper. 350 
When analyzing the data for case-control differences in grey matter correlates 351 
of anxiety/depression symptoms, we found significant reductions in regional grey 352 
matter volume in independent samples of patients with Depression (t-353 
statistic=4.61(612), p<0.001, Cohen’s D = 0.39, 95% CIs=0.25, ∞), Schizophrenia (t-354 
statistic=2.54(445), p=0.002, Cohen’s D=0.25, 95% CIs = 0.087, ∞) and in ADHD (t-355 
statistic=1.84(203), p=0.034, Cohen’s D=0.26, 95% CIs=0.030, ∞). In the executive 356 
dysfunction grey matter correlates, we found significant differences between patients 357 
and healthy controls in ADHD (t-statistic=2.19(203), p=0.014, Cohen’s D=0.32, 95% 358 
CIs=0.070, ∞), Schizophrenia (t-statistic=2.84(445), p=0.0026, Cohen’s D=0.28, 95% 359 
CIs=0.11, ∞) and Depression (t-statistic=1.65(612), p=0.050, Cohen’s D=0.14, 95% 360 
CIs=0.001, ∞). We did not find significant effects of bipolar disorder along either of 361 
these dimensions (t-statistic=-0.23(473), p=0.59, Cohen’s D=-0.02, 95% CIs=-0.17, 362 
∞) and (t-statistic=-1.33(473), p=0.90, Cohen’s D=-0.12, 95% CIs=-0.27, ∞) 363 
respectively (Figure 4). In these case-control analyses, the data distribution was 364 
assumed to be normal but this was not formally tested. To test whether the observed 365 
reduction in grey matter was specific to the brain correlates identified, as opposed to 366 
being a proxy for a generalized, brain-wide reduction in grey matter, we repeated the 367 
clinical comparisons using total grey matter as a covariate of no interest in addition 368 
to total intracranial volume (Supplementary Figure 10). ADHD and Depression 369 
results were unaffected by this change in pre-processing. In contrast, the 370 
Schizophrenia results were no longer significant. 371 
 372 
 373 
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 374 
Discussion 375 
We ran analyses to establish direct relations between psychiatric symptoms and 376 
neuroimaging measures of brain structure and function, without immediate reference 377 
to pre-defined psychiatric categories. This kind of dimensional, data-driven, 378 
approach is particularly relevant in adolescence where there is a good deal of 379 
evidence suggesting that psychopathology is less differentiated than in adulthood 380 
and therefore doesn’t fit into the traditional categorical conception of psychiatric 381 
disorder30,31. We find two largely non-overlapping sets of brain regions that correlate 382 
with different sets of psychiatric symptoms. The first symptom dimension 383 
predominantly encompassed anxiety/depression symptoms whilst the second 384 
dimension mainly consisted of executive dysfunction symptoms. 385 
The anxiety/depression canonical symptom correlate was significantly associated 386 
with T1, rs-fcMRI and DTI data modalities. Participants scoring highly on this 387 
psychiatric scale showed decreased grey matter volume in the middle temporal 388 
gyrus, reduced fractional anisotropy in the genu of the corpus callosum, and 389 
increased functional connectivity between the default mode network and the 390 
cerebellum. A recent meta-analysis has demonstrated an association of depression 391 
with the right inferior temporal gyrus22, a region exhibiting close connections with the 392 
limbic system, consistent with the  theory that depression results from dysfunctional 393 
cortico-limbic circuits32. The genu of the corpus callosum is a commisural white 394 
matter pathway that links left and right prefrontal brain regions33. Changes in the 395 
structure of the corpus callosum are known to result in altered inter-hemispheric 396 
connectivity and impaired emotional control34. The genu of the corpus callosum has 397 
been shown to be the white matter region with the largest difference in FA between 398 
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controls and patients with major depression35. The default-mode network is a set of 399 
brain regions that reliably exhibit a decrease in activity when the brain is engaged in 400 
non-self-directed tasks; this network is thought to be primarily responsible for self-401 
inspection and internal monitoring36,37, which are processes overactive in 402 
depression38. Increased connectivity between the default-mode network and the 403 
cerebellum has been previously reported in drug-naive depressive patients24, 404 
consistent with its recently discovered involvement in complex cognitive and 405 
emotional processes39. 406 
We found that the executive dysfunction psychiatric symptom group was significantly 407 
correlated with neuroimaging measures derived from T1 data. Here, decreased grey 408 
matter was localised to the Right Middle Temporal Gyrus, previously linked to 409 
ADHD25. These results are more difficult to interpret as the function of this brain area 410 
is not well studied. As with the rest of the temporal lobe, this brain area is thought to 411 
be responsible for generating meaning from sensory inputs19. Further, the temporal 412 
lobe functions in close relation with the hippocampus in the formation of memories19. 413 
Therefore, atrophied grey matter in this brain area may help explain the learning 414 
deficits often observed with ADHD-like symptoms.  415 
The identification of brain systems from a population-based cohort that is not 416 
suffering from any other psychiatric illness has major advantages: By identifying sub-417 
clinical correlates of psychiatric illness, prior to the full manifestation of disorder, it is 418 
possible to avoid the potential impact of effects indirectly related to illness, such as 419 
substance use and medication effects. For example, 17% percent of the 420 
schizophrenia, and 21% percent of the Bipolar samples but none of the healthy 421 
controls studied here have a history of alcohol abuse, which has been linked to 422 
widespread decreases in grey matter40. In addition, various psychiatric medicines, 423 
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including lithium, which is often prescribed to Bipolar patients, have also been linked 424 
to alterations in grey matter volume41, it is possible that lithium-induced increases in 425 
grey matter volume may have contributed to the observed absence of significant 426 
findings in Bipolar patients in this study.  427 
We compared the efficacy of the data-driven msCCA-regression method with 428 
pre-defined psychiatric scales of internalising and externalising symptoms. We found 429 
that the data driven approach identified relations between symptoms and the brain 430 
that were significantly stronger than a similar approach using standard internalising 431 
and externalising psychiatric symptom scales, defined without reference to any 432 
underlying biology. The fact that the canonical symptom groups show a stronger 433 
correlation with neuroimaging measures than pre-defined scales is important as it 434 
shows that data driven methods may offer the potential to refine existing psychiatric 435 
categorisations6. 436 
It is notable that grey matter correlates of psychopathology are already 437 
present at age 14 years, preceding the development of symptoms that only become 438 
manifest 5 years later, at 19 years. We also found that the brain correlates 439 
identified in the adolescent general population replicate in independent clinical 440 
samples of corresponding psychiatric disorders, namely depression and ADHD. In 441 
addition to validating  our primary results gained from population cohorts, these 442 
results raise  the prospect of using neuroimaging measures, discovered in preclinical 443 
samples, as predictors of future psychopathology, thus enabling the development of 444 
targeted interventions in a young age group, where such measures are most 445 
effective in reducing the burden of mental illness42. 446 
It is important to note that the results of the msCCA-regression analysis 447 
applied here, depend on the distribution of prevalence of psychopathological 448 
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symptoms in each sample investigated. Thus, while a general population sample 449 
may yield an index of the normative variance in psychiatric symptoms from 450 
a broader range of different psychiatric disorders and their neural correlates, a 451 
patient sample might yield a narrower biological stratification within distinct clinical 452 
psychiatric categories, e.g. different biotypes of depression5, or symptoms 453 
of psychosis. 454 
By basing symptom groups upon brain correlates, and by demonstrating 455 
specific associations of these correlates with clinical psychopathology, we have 456 
characterized stratification markers based on shared neural substrates. By 457 
discovering that these brain correlates identified in young adults are already 458 
established during adolescence, we have characterized biological risk markers prior 459 
to the manifestation of symptoms. Our work thus shows how major obstacles can be 460 
overcome in developing a taxonomy for psychiatric illness based on quantifiable 461 
neurobehavioral phenotypes. 462 
 463 
 464 
 465 
 466 
 467 
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 469 
 470 
 471 
 472 
 473 
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 479 
Methods 480 
Ethics Statement 481 
IMAGEN 482 
Each site sought and received approval from the relevant local research ethics 483 
committee. Written consent was obtained from each participant and a parent or 484 
guardian. 485 
Munich-Depression 486 
The studies were approved by the respective local ethics committees: The ethical 487 
committee of the Ludwig-Maximilians-Universität, Munich, Germany and the ethical 488 
committee of the Bayerische Landesärztekammer, Munich, Germany. All participants 489 
provided written informed consent. 490 
TOP 491 
All participants were recruited between 2003 and 2009 as part of an ongoing study of 492 
psychotic disorders (Thematically Organized Psychosis study). After complete 493 
description of the study, all participants gave informed consent to participate. The 494 
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study was approved by the Regional Committee for Medical Research Ethics and the 495 
Norwegian Data Inspectorate.  496 
ADHD 497 
This study was approved by the regional ethics committee (Centrale Commissie 498 
Mensgebonden Onderzoek: CMO Regio Arnhem – Nijmegen; 2008/163; ABR: 499 
NL23894.091.08) and the medical ethical committee of the VU University Medical 500 
Center. Informed written consent was obtained from each participant. For children 501 
under 18, both parents and children gave consent.  502 
Study Protocol 503 
We developed a method, termed msCCA-regression to find multivariate relationships 504 
between psychiatric symptoms, and multiple neuroimaging modalities 505 
simultaneously; In this case, voxel-based morphometry (VBM)18 measures of grey 506 
matter volume, fractional anisotropy (FA) derived from DTI data, and normalized 507 
using tract based spatial statistics (TBSS)19, and resting state functional connectivity 508 
neuroimaging measures43. msCCA-regression analysis was carried out in the 509 
general population IMAGEN sample, when participants were aged 19. Additional 510 
analyses were then applied in order to localize associations between psychiatric 511 
symptoms, and neuroimaging measures of brain structure and function. We then 512 
analyzed neuroimaging and symptom data at age 14 in order to determine whether 513 
this multivariate relationship already existed at this earlier time-point. Following this, 514 
we assessed the clinical significance of our findings by conducting case-control 515 
comparisons of the structural markers found in the IMAGEN analysis, in several 516 
clinical samples. The following text gives a more detailed description of the methods 517 
described here.  518 
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IMAGEN Analysis 519 
IMAGEN is a large-scale neuroimaging-genetics cohort study conducted with the aim 520 
of understanding the biological basis of individual variability in psychological and 521 
behavioural traits, and their relation to common psychiatric disorders44. The study 522 
involves a thorough neuropsychological, behavioural, clinical and environmental 523 
assessment of each participant. Participants also undergo biological 524 
characterisation, with the collection of T1 weighted MRI (sMRI), diffusion tensor 525 
imaging (DTI), task-based fMRI (t-fMRI), resting-state fMRI (rs-fcMRI) and genetic 526 
data. We used T1 weighted, DTI, and rs-fcMRI data in the current investigation.  527 
Participants 528 
The analysis was carried out on participants drawn from the IMAGEN sample (see 529 
for further details: Schumann et al44. For IMAGEN, a general population sample of 530 
Caucasian adolescents were recruited from eight sites across France, Ireland, 531 
England and Germany. Data was collected at age 14, 16 and 19 years. After a 532 
conservative quality control of MRI acquisitions and DAWBA questionnaires, 533 
participants with complete data were used in the subsequent data analysis. No 534 
statistical analyses were used to pre-define sample size. However, the sample size 535 
used was simlar to that reported in previous studies10,12.  536 
DAWBA 537 
Psychiatric symptoms of the IMAGEN participants were assessed using screening 538 
questions from the development and wellbeing assessment (DAWBA), a wide 539 
ranging psychiatric screening questionnaire45. Participants were asked screening 540 
questions, assessing symptoms of: specific fears, social fears, stress after a very 541 
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frightening event, obsessions and compulsions, worrying, depression, rapidly 542 
changing mood, attention and activity, troublesome behavior, drug and alcohol use, 543 
concern about appearance and strange/frightening experiences; if enough of these 544 
questions were answered in the affirmative, a more in-depth assessment of 545 
symptoms associated with that disorder was made. DAWBA screening questions 546 
have previously been used to define subthreshold clinical symptoms in neuroimaging 547 
studies of subclinical psychopathology46. The strength and difficulties questionnaire 548 
(SDQ) was also used in the present investigation as this questionnaire contributes to 549 
the assignment of diagnostic status in the DAWBA45. Questions in the SDQ are 550 
categorized into broad internalising and externalizing domains. The data of four of 551 
the questions asked had a standard deviation of zero amongst the participants 552 
asked, and were therefore not used in subsequent analyses. The full set of 553 
psychiatric questions asked in the present investigation can be found in 554 
Supplementary Table 1, the questionnaire items that were omitted from the analysis 555 
are marked here. At the time of the analysis conducted here, DAWBA/SDQ data had 556 
been collected for 1510 participants. Of these, data was incomplete for 239 557 
participants, and was not used. 558 
 559 
T1 Weighted MRI Acquisition 560 
Scanning took place at eight different sites across Europe, using scanners built by 561 
four different manufacturers (Siemens, Philips, General Electric, Bruker). High 562 
resolution, T1 weighted images were obtained using a Magnetization Prepared Rapid 563 
Acquisition Gradient Echo (MPRAGE) sequence, based on the ADNI protocol 564 
(http://www.loni.ucla.edu/ADNI/Cores/index.shtml). Scan parameters were 565 
standardized across sites to the highest degree possible (sagittal slice plane; 566 
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repetition time: 2.3 s; echo time 2.8 ms; flip angle 8°; 256×256×160 matrix; isotropic 567 
voxel size: 1.1 mm).  568 
VBM Pre-processing 569 
At the time this investigation was conducted, T1 data had been acquired for 1400 570 
participants. All scans were visually inspected and manually reoriented. 285 scans 571 
were discarded from the analysis for either movement artifacts, strong field 572 
inhomogeneities, abnormal field of view, abnormally reduced cerebellum and for 573 
brace artefacts. The resulting 1,115 scans were used to build the study specific 574 
template. Baseline and Follow up two scans were preprocessed using both the 2008 575 
version of the Voxel Based Morphometry toolbox (VBM8) running in SPM8 (v.5236). 576 
Given the young adults recruited in IMAGEN, we first used VBM8 in order to avoid 577 
using adult tissue probability maps (TPM) to initiate the segmentation process. The 578 
VBM8 toolbox segmentation relies on an adaptive Maximum a Posterior technique 579 
and TPMs used in VBM8 are for registration purposes only. Diffeomorphic 580 
registration (Dartel) was then used to register the 1,115 images, and to generate the 581 
study-specific population average template47. We then resliced the data to 582 
1.5x1.5x1.5mm voxel size. Smoothing was carried out using an isotropic 8 mm full 583 
width at half maximum Gaussian smoothing kernel. We created a mask for the 584 
sample by taking the mean across all VBM maps included in the sample. We 585 
thresholded the mask at >0.4. We used a stringent mask to avoid overfitting the 586 
data48.  We then extracted all voxel values within this mask, resulting in 241,544 grey 587 
matter voxels. 588 
DTI Acquisition 589 
 24
Diffusion    tensor    imaging    acquisition sequence based on the study by Jones et 590 
al49. Diffusion tensor images were acquired using an Echo Planar imaging sequence 591 
(b=0 and 32 directions with b-value 1300 s/mm2; axial slice plane; echo time = 592 
104ms; 128x128x60 matrix; voxel size 2.4x2.4x2.4 mm), adapted to tensor 593 
measurements (for example, FA, mean diffusivity (MD)) and tractography analysis. 594 
 595 
TBSS Pre-processing 596 
At the time this study was conducted, DTI data had been acquired for 1412 597 
participants. Of these, 71 were not usable due to: signal dropouts or too much 598 
rotation. Diffusion imaging data was pre-processed using software from the FSL 599 
toolbox (www.fmrib.ox.ac.uk/fsl)50. We preprocessed the remaining 1341 scans 600 
using tract based spatial statistics (TBSS)19. Pre-processing was carried out in the 601 
following manner: An affine registration was applied to the first B0 image for head 602 
motion and eddy current correction. Brain extraction was carried out using BET. 603 
Diffusion tensor fitting was then used to obtain fractional anisotropy (FA) maps for 604 
each participant. All participants’ FA data was aligned into a common space using 605 
the non-linear registration tool FNIRT, using a b-spline representation of the 606 
registration warp field. The mean was then taken across all FA maps to create an FA 607 
averaged image. This map was then ‘thinned’ to create a mean FA skeleton, which 608 
was then thresholded at FA > 0.2, keeping only the major white matter tracts. Each 609 
participant’s aligned FA data was then projected onto the mean skeleton. We then 610 
used these skeletonised maps in all subsequent analyses. The final mask used 611 
contained 106,812 voxels. A further 10 scans were not used due to masking or 612 
normalization issues in TBSS. 613 
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Resting State fMRI Acquisition  614 
Resting state fMRI scanning of the IMAGEN participants was carried out at multiple 615 
sites. The following parameters were standardized: number of volumes (164), TR = 616 
2.2s, TE = 30ms, flip angle = 75, number of slices/ddas = 40/3, slice thickness = 2.4 617 
mm, slice gap = 3.4 mm, voxel size = 3.4 x 3.4 x 2.4 mm3, matrix size = 642, FOV = 618 
218 mm. 619 
Resting State fMRI Preprocessing  620 
At the time of this investigation, we had collected rsfMRI scans for 1067 participants. 621 
Of these scans, 157 were not used, either because over 5% of scans in that 622 
participant exhibited artifacts of some kind, or if over 5% of volumes showed a 623 
fractional displacement of over 0.5mm. Preprocessing of resting-state data was 624 
performed with routines from FMRIB’s Software Library (FSL v5.0.9)50 and Advanced 625 
Normalization Tools (ANTs v1.9.2)51. 626 
1) Motion correction was carried out, applying a rigid body registration of each 627 
volume to the middle volume (FSL MCFLIRT). 628 
2) Non-brain tissue was removed (FSL BET). 629 
3) Spatial smoothing was applied using a 5mm FWHM Gaussian kernel. 630 
4) Independent component analysis (FSL MELODIC) was run for each data set. 631 
Artifact components were identified using an automatic classification 632 
algorithm, and subsequently regressed from the data (ICA-AROMA v0.3)52,53. 633 
ICA-AROMA52 has been shown to be as effective as motion parameter 634 
regression, with additional spike regression and ‘scrubbing’, in the removal of 635 
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motion related effects on functional connectivity measures derived from 636 
resting state fMRI data. However, this procedure has the additional benefit 637 
that it preserves more signal of interest than these methods53. 638 
5) The resulting cleaned data set was de-trended (up to a third degree 639 
polynomial).  640 
6) Co-registration to a high-resolution T1 image (FSL FLIRT using the BBR 641 
algorithm), and normalization to 2mm isotropic MNI standard space (ANTs) 642 
was carried out. 643 
7) We used the CompCorr procedure to further clean the data of physiological 644 
noise54. To do this: we created white matter (WM) and cerebrospinal fluid 645 
(CSF) masks by taking the mean of the WM and CSF segmentations from the 646 
VBM analysis, and thresholding them at 0.95, we then resliced these maps 647 
into the same space as the rsfMRI data. We then extracted timecourses from 648 
voxels within these regions, and took the first three principal components of 649 
this signal for both WM and CSF maps. These six principal component signals 650 
should represent non-neuronal signal. We then regressed this non-neuronal 651 
signal from voxel timecourses across the rest of the brain.  652 
8) Lastly, preprocessed and normalized resting-state data sets were resliced to 653 
3mm isotropic voxels. 654 
 655 
 656 
Mapping rs-fMRI data 657 
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1) We first generated 55 regional nodal timecourses using dual regression on 658 
nodal regions established in the UK biobank sample17. 659 
2) We mapped the correlation between nodal regions using Pearson’s pairwise 660 
correlation coefficient, for each participant, thus producing a connectivity 661 
matrix for each participant. This connectivity matrix consists of 1,485 662 
connections between nodes. 663 
3) We then transformed these connectivity values using Fisher’s Z-score 664 
transform. 665 
Different Neuroimaging Processing Strategies 666 
A wide range of different preprocessing strategies can be applied in the analysis of 667 
neuroimaging data. Approaches to analysing DTI and T1 can be categorised into two 668 
broad types: voxelwise, and atlas based approaches18,55. We chose to analyse this 669 
data at the voxelwise level, as this allows for the highest level of spatial specificity. 670 
Although it is also technically possible to analyse rs-fcMRI data across the whole 671 
brain at the voxelwise level, this approach results in an enormous number of 672 
features: When mapping connectivity at the voxelwise level, in a dataset made up of 673 
N voxels, we are left with (N*(N-1))/2 connections between those voxels. In the 674 
current investigation, N = 57,053, leading to N*(N-1)/2 = 1.63 billion inter-regional 675 
connections. This would lead to a huge amount of redundancy in the data and 676 
computational, statistical and interpretational issues. For this reason, we mapped the 677 
connectivity between a pre-defined set of nodes. We used nodal definitions resulting 678 
from previous work applying independent component analysis (ICA) to the UK 679 
biobank sample17. We used this nodal definition as it derives from the largest extant 680 
sample of neuroimaging data. In order to test whether the results we obtained were 681 
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robust to different nodal definitions, we also mapped inter-regional connectivity using 682 
the widely used Power atlas56 and achieved similar results (Supplementary Figure 683 
6).  684 
Canonical Correlation Analysis and Sparse Canonical Correlation Analysis 685 
Canonical correlation analysis (CCA) is a very general statistical method used to 686 
identify linear relationships between two or more sets of variables57. It can be 687 
thought of as a generalization of multiple linear regression. The objective of CCA is 688 
to identify a relationship between two (or more) sets of variables, where there is no 689 
distinction between which variables are considered dependent, and which are 690 
considered independent. This method identifies weights for each variable, such that 691 
the weighted sum of variables in each set is maximally correlated with the weighted 692 
sum of variables from the opposite set, assuming a linear relationship. 693 
Consider two matrices ࢄଵand ࢄଶ, where each row denotes one of n observations, 694 
and each column denotes one of p1 or p2 features. CCA seeks to find the weight 695 
vectors ࢝ଵ and ࢝ଶ that maximise the correlation: 696 
ߩ = ܿ݋ݎݎ(ࢄଵ࢝ଵ, ࢄଶ࢝ଶ). 697 
This optimisation problem can be written as: 698 
ߩ = ݉ܽݔ࢝భ,࢝మ	࢝ଵࢀࢄଵࢀࢄଶ࢝ଶ 
Subject to the constraints: 699 
࢝ଵ்ࢄଵࢀࢄଵ࢝ଵ = 1 and ࢝ଶࢀࢄଶ்ࢄଶ࢝ଶ = 1. 700 
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We assume that the columns of ࢄଵ andࢄଶ have been standardised to have a mean of 701 
zero and a standard deviation of one. The vectors ࢄଵ࢝ଵ and ࢄ࢝ଶ are referred to as 702 
canonical variates.  703 
Classical CCA is extremely powerful, but cannot be applied in situations where there 704 
are a more features than samples (i.e., p1 > n or p2 > n, which is typically the case in 705 
neuroimaging studies). Interpreting and describing results from CCA can be difficult 706 
because the estimated weights are not sparse. This means that some variables may 707 
make negligible but non-zero contributions to the variance explained between sets. 708 
Sparse canonical correlation analysis (sCCA) was developed to address these 709 
issues11,58,59.  710 
sCCA uses an L1 penalty on canonical weights, which forces some of them to take a 711 
value of exactly zero. Furthermore, sCCA can also be applied in scenarios where 712 
there are more features than samples (p > n). The optimization criteria for sCCA can 713 
be written in the following manner: 714 
ߩ = ݉ܽݔ࢝భ,࢝మ࢝ଵ்ࢄଵ்ࢄଶ࢝ଶ 
Subject to the constraints: 715 
‖࢝ଵ‖ଶ = 1, ‖࢝ଶ‖ଶ = 1 , ‖࢝ଵ‖ଵ ≤ ܿଵ  and ‖࢝ଶ‖ଵ ≤ ܿଶ 716 
Here, ܿଵ and ܿଶ are assumed to fall within the bounds  1 ≤ ܿଵ ≤ √݌ଵ and 1 ≤ ܿଶ ≤ √݌ଶ, 717 
where ݌ଵ and ݌ଶ are the number of features in views ଵܺ  and ܺଶ  respectively. 718 
Multiple Sparse Canonical Correlation Analysis Regression 719 
The formulation of sparse canonical correlation analysis described in the text above 720 
is designed to find relations between two views of a dataset. However, we have 721 
 30
collected data from several different neuroimaging modalities, and would like to 722 
utilize information from each of them. A somewhat naive approach to finding 723 
relations between psychiatric symptoms and multiple neuroimaging measures would 724 
be to include all available neuroimaging modalities in one view of the canonical 725 
relation, with psychiatric symptoms in the other view. However, this approach is likely 726 
to be problematic as different modalities are associated with very different numbers 727 
of features. For example, the functional connectivity data used in the present 728 
investigation has only 0.6% of the number of features that the VBM data has. As 729 
such, if these modalities were entered into the same model, the VBM data would 730 
overwhelm the functional connectivity data.  731 
We developed an approach designed to maximise the cross-correlation between 732 
psychiatric symptoms, and multiple neuroimaging modalities simultaneously, we then 733 
combined these modalities in a linear regression model. Formulations of canonical 734 
correlation analysis that are able to find relations between more than two sets of data 735 
are termed multiple or generalised canonical correlation procedures. A widely used 736 
optimisation criteria for multiple canonical correlation analysis is to maximise the sum 737 
of correlations between each of the different views of a dataset60. Witten et al have 738 
formulated a sparse version of multiple canonical correlation analysis58; this 739 
formulation is designed to maximise the sum of correlations between all views of the 740 
data. However, in the present investigation, we are only interested in finding 741 
correlations between neuroimaging measures, and psychiatric questionnaire 742 
responses; we do not wish to optimise the correlation between different 743 
neuroimaging measures.  744 
As such, we seek to maximise the following relation: 745 
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݉ܽݔ࢝భ,..,࢝࢔࢝ଵ்ࢄଵ்෍ࢄ࢏࢝௜
࢔
࢏ୀଶ
 
Subject to the constraints: 746 
‖࢝ଵ‖ଶ = 1, ‖࢝௜‖ଶ = 1 , ‖࢝ଵ‖ଵ ≤ ܿଵ  and ‖࢝௜‖ଵ ≤ ܿ௜ 747 
This method simultaneously optimizes the correlation between a weighted sum of 748 
variables in the target set, X1, with a weighted sum of variables in the other sets. In 749 
the present investigation, X1 is a matrix of psychiatric symptoms and X2 to Xn are 750 
neuroimaging measures of brain structure and function. Using this method, we are 751 
able to maximise the correlation between psychiatric symptoms, and several 752 
different neuroimaging modalities within the same integrated model. A natural choice 753 
for the statistic of interest, in any inference carried out using this procedure, would be 754 
the sum of correlations between the symptom data, and the neuroimaging measures 755 
of brain structure and function. However, a sum of correlations is of less practical 756 
benefit than understanding how much total variance is shared between 757 
neuroimaging measures of brain structure and function, and psychiatric symptoms. 758 
Therefore, in the final step of this process, we combine canonical neuroimaging 759 
variables in an ordinary linear regression model. Canonical variables are defined as: 760 
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ܥ௜ = ௜ܺݓ௜	
Canonical variables are then combined in the prediction of psychiatric symptoms 761 
using ordinary linear regression: 762 
ܥଵ = ߚ଴ + ܥଶߚଶ …+ ܥ௡ߚ௡ + ߳ 
We used this approach to establish relations between psychiatric symptoms (C1), 763 
and TBSS (C2), VBM (C3), and connectivity measures (C4) derived from rs-fMRI data 764 
and ߚ௡ are the associated weights estimated using ordinary linear regression (ߚ଴ is 765 
the constant estimated in regression). 766 
msCCA-regression was carried out using in-house codes written in MATLAB. This 767 
algorithm requires an initialization value. In the present study, initial weights were 768 
randomly generated. Weight values associated with psychiatric symptoms were 769 
always constrained to be positive to ensure interpretability.  770 
This study is designed to be exploratory in nature. Nevertheless, given the very large 771 
quantity of data we sought to integrate, it is likely that some simple priors will help to 772 
improve the stability of our results, so long as those priors are well supported. There 773 
is a great deal of evidence suggesting that psychopathology is associated with 774 
decreases in both grey matter, and fractional anisotropy, across psychiatric 775 
disorders61,62. For this reason, we constrained the canonical weights on VBM volume 776 
and FA to be negative. This will help to reduce variance in the model and will help 777 
increase interpretability of our results. In contrast, there is no clear evidence that 778 
psychiatric illness is associated with increases or decreases in connectivity 779 
measures derived from BOLD-fMRI. Therefore, we did not add constraints to the 780 
functional connectivity data. 781 
 782 
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Stability Selection  783 
Although msCCA-regression (and sCCA) have advantages over classical CCA in 784 
terms of interpretability, it can suffer from instabilities due to their utilization of an L1 785 
penalty to introduce sparsity21. This is particularly true when p >> n, and when there 786 
is a high degree of collinearity in the data. Stability selection is a widely applicable 787 
feature selection procedure that can address this problem21.  This procedure has the 788 
added benefit that it makes the results less sensitive to the choice of L1 penalty.  789 
The conceptual underpinning of stability selection is very simple: if a model is 790 
repeatedly resampled, features exhibiting a ‘real’ effect will be selected more often 791 
than noise. Using stability selection, data is repeatedly split into random sub-samples 792 
of size nt/2 (where nt is the total number of participants in the training dataset). In this 793 
work, resampling was carried out a hundred times. msCCA was applied to each 794 
resample, and those features that appear more often are deemed to be more stable. 795 
Deciding which variables are stable requires a threshold: ߨ௥ is defined as the fraction 796 
of samples in which a particular variable must be observed to be considered stable. 797 
We set ߨ௥ to 0.9, which means that a particular variable must be present in 90% of 798 
resamples to be considered stable. The outcome of this stability selection procedure 799 
is a set of stable features. A benefit of stability selection is that it is insensitive to 800 
tuning parameters. Here, we simply set the L1 penalty at ඥ݌/2	, which is halfway 801 
along the regularization path running from 1 to ඥ݌ . It is worth noting that the stability 802 
selection procedure is easily parallelizable here as it simply involves re-applying the 803 
msCCA-regression algorithm to multiple different resamples of the same data.  804 
 805 
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Analysis Design 806 
The L1 penalty used in sCCA means that the parametric tests used for significance 807 
testing in classical CCA (for example Wilk’s Lambda)63 cannot be used here, 808 
necessitating the use of permutation testing to determine whether results are 809 
significant. We assessed the in-sample significance of the results we obtained here, 810 
then replicated these findings using an out-of-sample, hold-out set design. This kind 811 
of experimental design has a number of advantages in the present context: using a 812 
training/testing design, it is possible to obtain an unbiased estimate of effect size. We 813 
used a hold-out set design in preference to a cross-validation procedure. This is 814 
because cross-validation involves the training and testing of multiple statistical 815 
models, one for each cross-validation fold, which precludes the use of a single model 816 
for further validation/characterization. A related advantage is that it is possible to 817 
carry out further characterization of the test set results, due to the fact that we are 818 
able to estimate effect size in an unbiased way. 819 
In detail, the analysis design was carried out as follows: 820 
1) Psychiatric symptom data, and data from the VBM, TBSS and rs-fcMRI 821 
neuroimaging modalities was extracted and transformed into ݊௧ x pi matrices, 822 
where ݊௧ is the number of participants included in the training dataset, and pi 823 
is the number of features included in each of the views of the data.  824 
2) The full dataset was randomly split into training and testing sets. The training 825 
set was made up of 70% of the data whilst the testing set was made up of the 826 
remaining 30%.  827 
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3) The training data was then randomly split into a hundred further resamples. 828 
Each resample was made up of nt/2 participant scans, where nt is the total 829 
number of participants in the training dataset. 830 
4) The first stage of the mSCCA- regression algorithm (see above) was then 831 
applied to each resample, with a sparsity constraint of √݌௜/2 in each view of 832 
the data. 833 
5) We then recorded which variables, in each view of the data, are present in 834 
over 90% of resamples. These variables are considered to be stable, and are 835 
retained. 836 
6) We then re-applied the msCCA algorithm to the data, without sparsity 837 
constraints, on the variables than survived more than 90% of resamples.  838 
7)  We then combined the neuroimaging canonical variates we found in the 839 
previous step in a prediction model on the symptom canonical variate, using 840 
ordinary least squares regression. We then recorded the correlation between 841 
the neuroimaging prediction model, and the symptom canonical correlate. 842 
8) We then permuted the training data, and repeated steps 3-7. This was done 843 
for 10,000 different permutations of the training data labelling. In each case, 844 
we recorded the correlation between the neuroimaging model, and the 845 
canonical correlate of psychiatric symptoms. In this way, we built up a 846 
permutation distribution to assess the significance of the relation between 847 
symptom and neuroimaging data in the experimental labelling, within the 848 
training dataset.   849 
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9) We then applied the trained model to the test set to produce canonical 850 
correlates of symptom and neuroimaging measures. We recorded 851 
associations for both the full model, and between the psychiatric symptom 852 
score, and each of the individual neuroimaging canonical correlates.  853 
10)  We then randomly permuted the data rows in the testing set and re-854 
calculated correlation values between symptom and brain canonical 855 
correlates. We recorded associations between psychiatric symptoms and the 856 
full neuroimaging model, for each of 10,000 permutations of the experimental 857 
labelling.  858 
11) It is also interesting to find the significance of the individual neuroimaging 859 
modalities. However, as we are testing the significance of multiple 860 
neuroimaging modalities, it is necessary to correct for multiple comparisons 861 
across these different modalities. This is easily done using the distribution of 862 
the maximal statistic: for each permutation of the experimental labelling, we 863 
calculate the association between the symptom score and each of the 864 
neuroimaging canonical correlates; the largest of these associations is then 865 
recorded. This is done for each of the 10,000 permutations of the test 866 
labelling, producing a distribution of the maximal statistic. Correlations 867 
between symptom and neuroimaging measures in the experimental labelling 868 
are then significant at the FWE-corrected level α if they are above the 100*(1- 869 
α) percentile of this distribution.   870 
This process is illustrated in Supplementary Figure 1. 871 
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Confounds 873 
It is important to account for the effects of confounds, which might otherwise lead to 874 
spurious relations between the different data views64. Here, we regressed age, 875 
gender, site and intracranial volume from all data views prior to the sCCA analysis65-876 
67. For the connectivity measures derived from rsfMRI data, we also regressed the 877 
mean between-volume fractional displacement, and the percent of slices corrupted 878 
by artefacts, from the scans. 879 
Additional Analyses to Localise Effects 880 
We used msCCA-regression to find multivariate relations between psychiatric 881 
symptomatology and neuroimaging measures of brain structure and function. In 882 
using msCCA-regression, it is possible to make inferences on relations between sets 883 
of psychiatric symptoms and neuroimaging measures across the brain, it is not 884 
possible to make inferences on individual brain regions/connections or individual 885 
questionnaire items. For this reason, we conducted additional analyses to further 886 
deconstruct the relationship between psychiatric symptomatology and the brain. This 887 
procedure is similar to a redundancy analysis68,69. In particular, we were interested in 888 
localising which brain regions exhibited an individually significant association with 889 
psychiatric symptomatology.  890 
Conducting further tests on the whole dataset would introduce circularity into the 891 
analysis. Therefore, additional inference must be carried out on the testing dataset 892 
alone. Nevertheless, the training dataset is still likely to contain useful information, 893 
which can be used to guide analyses carried out on the testing dataset, thus 894 
decreasing the multiple comparison problem, and increasing the likelihood of finding 895 
significant effects in the testing dataset. In the present investigation, we looked for 896 
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significant localizable effects in the training dataset, we then used these results to 897 
inform analyses carried out on the testing dataset. In this sense, the training dataset 898 
was used as a ‘discovery dataset’.  899 
In the case of the TBSS and VBM data, we sought to localize associations between 900 
symptoms and the brain to the cluster-wise level. In the case of the rs-fcMRI data, 901 
we sought to localize changes to individual inter-regional connections. VBM and 902 
TBSS clusters were defined using an 18-connectivity scheme. This means that 903 
voxels must be connected by a face or an edge to be considered a part of the same 904 
cluster.  905 
This analysis was carried out in the manner described below: 906 
1) We calculated the grey matter volume and FA in spatially distinct clusters 907 
identified in the sCCA analysis applied to VBM and TBSS respectively. We 908 
extracted connectivity values with non-zero canonical weights. This was done 909 
in both the training and testing datasets.  910 
2) We calculated Pearson’s correlation coefficient between the mean of each 911 
spatially distinct cluster/connection, and the sum of symptom score values. 912 
This was done separately in the training and testing datasets. 913 
3) Rows associated with neuroimaging data in the training set were permuted 914 
and correlations between clusters/connections, and symptom clusters were 915 
recalculated. The maximal value was recorded. Training data was permuted 916 
10,000 times; the maximum correlation value across all clusters/connections 917 
was recorded for each permutation. Clusters/connections exhibiting a 918 
significant effect in the training dataset were then determined by comparing 919 
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correlation values to the distribution of the maximal statistic50, 51. Because 920 
model selection was carried out in the training dataset, conducting inference 921 
on the training dataset would constitute “double dipping”.  922 
4) Clusters/connections exhibiting a significant effect in the training dataset were 923 
taken forward for an analysis carried out in the testing set.  924 
5) We calculated correlation values between clusters/connections in the testing 925 
dataset, and the symptom score.  926 
6) Testing data was permuted 10,000 times; the maximum correlation value 927 
across all clusters/connections was recorded for each permutation. 928 
Clusters/connections exhibiting a significant effect in the testing dataset were 929 
determined by comparing correlation values to the distribution of the maximal 930 
statistic. Cluster/connection correlations in the testing dataset were then 931 
compared to correlations in the distribution of the maximal statistic. 932 
Cluster/connection correlations in the experimental labelling, which were in 933 
the top 5% of the distribution of the maximal statistic, were considered 934 
significant at the FWE corrected level.  935 
This process is illustrated in Supplementary Figure 3. 936 
Finding Multiple Modes of Variation 937 
Using canonical correlation analysis, it is possible to uncover multiple modes of 938 
variation between datasets. After determining the significance of the first canonical 939 
correlate, we remove the effect of the first set of canonical vectors, and repeat the 940 
analysis. Witten et al used Hoteling’s deflation to remove the effect of the first vector; 941 
this approach has been criticized by Monteiro et al, who propose the projection 942 
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deflation procedure as an alternative11,70; this is the procedure we use in the present 943 
investigation. Correlations between the different canonical relations are given in 944 
Supplementary Table 6. 945 
It is possible to ascertain the significance of all canonical relations after the first by 946 
comparing the correlations of subsequent associations to the permutation distribution 947 
of the first relation: The first canonical relation between sets is by definition the 948 
strongest; any subsequent associations between sets will be weaker than the 949 
canonical relation that preceded it. A common means of correcting for multiple 950 
comparisons is to compare test statistics in the experimental labelling to the maximal 951 
statistic across all tests in the permutation distribution; this distribution is usually 952 
termed the distribution of the maximal statistic71,72. In the present investigation, we 953 
can find this distribution by recording the strength of the first canonical relation, for 954 
each permutation. Significance values that are corrected for multiple comparisons 955 
can then be found by comparing associations of subsequent modes of variation, with 956 
this distribution73. 957 
Hypothesis Driven Analysis 958 
A major advantage of the approach described here is that it allows the grouping of 959 
psychiatric illnesses to be driven by their biological underpinnings. Nevertheless, it is 960 
an open question whether the symptom groups discovered in the data driven 961 
analysis we ran here show a stronger relation to neuroimaging measures of brain 962 
structure and function than pre-defined symptom groups. For this reason, we tested 963 
whether the widely used internalising/externalising organisation of psychiatric illness 964 
is able to explain as much variance in psychiatric symptomatology as this purely data 965 
driven method. To do this, we used an approach that is as similar as possible to the 966 
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primary data analysis followed in the main part of the investigation, yet still makes 967 
use of the internalising/externalising illness structure: we replaced the symptom 968 
matrices used in the main part of the investigation with symptom vectors based on 969 
previously defined internalising and externalizing symptom sub-scales from the 970 
DAWBA; no sparsity was applied to psychiatric symptom sub-scales. Used in this 971 
manner, the msCCA-algorithm reduces to something like a sparse partial least 972 
squares regression74, where the neuroimaging features are predictors and the pre-973 
defined internalising/externalising vectors are the targets.  This method was applied 974 
twice, once to predict the internalising symptom dimension, and once to predict the 975 
externalising. We term the internalizing and externalising symptom scales as 976 
DAWBA-internalising and DAWBA-externalising respectively. We defined symptoms 977 
as belonging to broad internalising or externalising categories in the same way as 978 
Aebi et al75 : The DAWBA-internalising scale was created by summing: specific 979 
fears, social fears, panic attacks, stress after a frightening event, worrying and 980 
depression. The DAWBA-externalising scale was created by summing: Attention and 981 
activity, behaviours and attitudes that can get people into trouble, and Cigarettes, 982 
Alcohol and Drugs sections of the DAWBA. The SDQ is already split into broad 983 
internalising and externalising domains45. Therefore, internalising and externalising 984 
SDQ scores were simply added to these scores to create DAWBA-internalising and 985 
DAWBA-externalising scores respectively. The sections: rapidly changing mood, 986 
dieting and bingeing and strange experiences that are surprisingly common were not 987 
used to create scores as these symptoms do not fit neatly into an 988 
internalising/externalising dichotomy. All of these questions can be found in 989 
Supplementary Table 1. 990 
 991 
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Longitudinal Analysis 992 
The msCCA-regression analysis described above was used to find relations between 993 
psychiatric symptoms and neuroimaging measures of brain structure at age 19, 994 
when participants were young adults. However, the developmental time period 995 
immediately preceding this time point is also of potential interest, with the brain going 996 
through important maturational processes and participants being at increased risk for 997 
the development of psychopathology76. Thus, we applied the msCCA-regression 998 
algorithm between psychiatric symptoms and neuroimaging measures at age 14. 999 
The results of this analysis are show in Supplementary Figure 8. We did not find a 1000 
significant relation between psychiatric symptoms and the brain at this age. As rs-1001 
fMRI data is only available for a small sub-sample of the full dataset at age 14, we 1002 
only used VBM and TBSS data in this analysis.   1003 
It is possible that neuroimaging markers of psychiatric illness precede the 1004 
development of full-blown psychiatric symptomatology. To determine whether this 1005 
was the case in the present investigation, we took the TBSS and VBM regions 1006 
identified as being associated with psychopathology at age 19, we then extracted the 1007 
appropriate neuroimaging data from these brain regions at age 14, and correlated 1008 
the output with symptoms at age 19. In this way, we showed that neuroimaging 1009 
measures at age 14 have predictive value for psychopathology at age 19.  1010 
For these analyses, we used the same subjects as were included in our 1011 
analysis at age 19. We also used the same train-test split within this subject group. 1012 
We subjected this age 14 data to the same QC procedures as the data taken at age 1013 
19. Of the n = 666 subjects used in the msCCA-regression analysis carried out at 1014 
age 19, 72 subjects had data that did not pass QC at age 14. This left n = 594 1015 
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subjects for age 14 analyses, with n = 412 subjects in the training group and n = 182 1016 
in the testing/replication group. 1017 
Clinical Analyses 1018 
Using mSCCA-regression, we found a set of neuroimaging features that correlate 1019 
with a set of questions assessing psychiatric health.  At the group level, participants 1020 
who score more highly on the vector derived from neuroimaging data will suffer a 1021 
larger number of psychiatric symptoms (as measured by the DAWBA). It might 1022 
therefore be expected that participants with a clinical diagnosis of a psychiatric 1023 
disorder would score more highly on this neuroimaging vector than healthy controls.  1024 
To discover whether this was the case, we subjected clinical data to exactly the 1025 
same pre-processing as the IMAGEN data; we then looked for changes in grey 1026 
matter volume in the regions identified in the initial analysis. A (one-sided) two-1027 
sample t-test was used to determine whether patients and controls differed 1028 
significantly on this one-dimensional measure. We only used grey matter data here 1029 
as this data-type showed the strongest relation to psychopathology in the IMAGEN 1030 
sample. Furthermore, this data-type is widely available and the number of degrees of 1031 
freedom in the MRI scan acquisition parameters is low. The case-control tests we 1032 
used here make the assumption of data normality, although this was not formally 1033 
tested here. 1034 
We used the same confounds in this analysis as we did on the IMAGEN data, this 1035 
includes the use of total grey matter as a covariate of no interest. However, it could 1036 
still be argued that regional changes are only acting as a proxy for total grey matter. 1037 
In order to determine whether this is the case, we repeated all pertinent analyses, 1038 
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using total grey matter as a regressor in addition to total intracranial volume. The 1039 
results of these analyses are shown in Supplementary Figure 10. 1040 
 1041 
Depression sample 1042 
The Munich sample consisted of patients with first episode and recurrent unipolar 1043 
Depression treated as in-patients at the Max Planck Institute of Psychiatry, Munich, 1044 
and healthy control participants. The data for 13 of the participants assessed was not 1045 
used as it was deemed to be of insufficient quality, this left: N=614; 400 patients, age 1046 
48 [SD 13.8] years, 53% women; 214 control participants age 49 [SD 13.3] years, 1047 
58% women, for the most part overlapping with imaging genetic and MDD 1048 
association studies reported in collaboration with the ENIGMA consortium22,77. Other 1049 
than in the two flagship studies, no bipolar patients were included for reasons of 1050 
clinical homogeneity. MDD diagnoses were based on clinical consensus in addition 1051 
to M-CIDI or SCAN interviews, depending on the original study protocols. The 1052 
Munich sample comprised images acquired in subsamples of the Munich 1053 
Antidepressant Response Signature Study and the Recurrent Unipolar Depression 1054 
Case-Control study, both performed at the MPIP. We did not use any statistical 1055 
analyses to decide on the sample size used here. However, the sample used was 1056 
among the largest of any single study investigating alterations in brain structure in 1057 
depressed participants77. 1058 
Schizophrenia/Bipolar sample 1059 
Participants with schizophrenia and bipolar disorder were recruited from the 1060 
Thematically Organised Psychosis (TOP) study. This is a collaborative study based 1061 
at the University of Oslo in Norway. The data for 2 participants was not used as it 1062 
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was considered to be of insufficient quality, this left: 286 Controls (aged 34 [SD 9.5] 1063 
years, 46% women), 161 Schizophrenics (aged 32 [SD 8.8] years, 35% women) and 1064 
189 participants with Bipolar Disorder (aged 34 [SD 11.5] years, 58% women). 1065 
Patients were recruited from the psychiatric unit of Oslo University Hospital and were 1066 
assessed for psychiatric illness with the Structural Clinical Interview for DSM-IV Axis 1067 
I disorders (SCID-I). This assessment was either administered by an MD, or a 1068 
clinically trained psychologist, and was used to assess the presence of AXIS I 1069 
disorders. Before participation, control participants were screened to exclude serious 1070 
somatic and psychiatric illness, substance abuse, or MRI-incompatibility. All 1071 
participants gave written informed consent before participation. Further information 1072 
about this sample and the scan protocols used can be found in Rimol, L. M. et al78. 1073 
We did not use any statistical methods to pre-define the sample size used in this 1074 
investigation. Nevertheless, the sample used is among the largest of any 1075 
investigating structural brain alterations in Schizophrenia79  and Bipolar disorder41 1076 
ADHD sample 1077 
Data for the ADHD sample was taken from the NeuroIMAGE project, a clinical cohort 1078 
study. The study is made up of individuals tested at two different sites in the 1079 
Netherlands, The Donders Centre for Cognitive Neuroimaging in Nijmegen, and the 1080 
Vrije Universiteit in Amsterdam. The total sample consisted of 184 participants 1081 
suffering from ADHD, 103 unaffected siblings, and 128 healthy controls. Further 1082 
information on the participants and the protocols used can be found in von Rhein et 1083 
al80. This sample includes a number of very young participants, which is likely to 1084 
introduce a large degree of heterogeneity into the analysis. For this reason, we did 1085 
not analyse the data from participants under the age of fifteen. This age divide point 1086 
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was considered to offer a reasonable trade-off between sample homogeneity and 1087 
size. The data for 12 of the participants was not used as it was deemed to be of 1088 
insufficient quality. Case-control Analyses were made between 74 healthy controls 1089 
(aged 18 [SD 2.0] years, 50% women) and 131 ADHD participants (aged 18 [SD 2.3] 1090 
years, 27% women). No formal statistical methods were used to determine the size 1091 
of this sample. However, this sample is large compared to similar samples 1092 
investigating case-control differences in brain structure in patients with ADHD81. 1093 
 1094 
 1095 
 1096 
 1097 
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Data Availability Statement 1099 
IMAGEN data used in this investigation will be made available upon reasonable 1100 
request to the corresponding author. All other data is available upon reasonable 1101 
request addressed to the appropriate study leads. 1102 
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Code Availability Statement 1104 
The core code used to run the analyses reported in this study are available as 1105 
Supplementary Software. Supporting code can be found at: 1106 
https://github.com/alexjamesing/mscca-regression-code. 1107 
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neuroimaging measures of r = 0.59(465) (p = < 0.001) in the training set, and associations between 1365 
symptoms and the brain of r=0.23(197), p<0.001, 95% CIs=0.13, ∞ in the test set; (b): Shows the 1366 
msCCA-regression model linking psychiatric symptoms with the different neuroimaging measures (c): 1367 
Psychiatric symptoms contributing to this relation are shown on the left, their canonical weights are 1368 
shown in red. (d): rs-fcMRI measures of functional connectivity. (e): VBM measures of grey matter 1369 
volume associated with symptoms. (f): TBSS measures of fractional anisotropy (FA).  1370 
 1371 
Figure 2: Results of the second msCCA-regression analyses showing relations between executive 1372 
dysfunction symptoms and neuroimaging measures in the IMAGEN sample, following the removal of 1373 
the first canonical relation. (a): The full msCCA-regression model linking psychiatric symptoms to 1374 
VBM, TBSS and rs-fcMRI neuroimaging measures at age 19. We found associations between 1375 
executive dysfunction symptoms and neuroimaging measures of r = 0.46 (p = 0.004) in the training 1376 
set, and associations between symptoms and the brain of r = 0.19(197), p = 0.002, 95% CIs =0.087, 1377 
∞ in the test set; (b) msCCA-regression model linking psychiatric symptoms with the different 1378 
neuroimaging measures  (c) Symptoms contributing to this relation are shown on the left their 1379 
canonical weights are shown in red. (d) rs-fcMRI measures of functional connectivity. (e) VBM 1380 
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measures of grey matter volume associated with symptoms. (f): TBSS measures of fractional 1381 
anisotropy (FA).  1382 
 1383 
Figure 3: Longitudinal analysis of canonical correlates. (a) anxiety/depression symptom correlates: 1384 
VBM and TBSS brain correlates established at age 19 are associated with anxiety/depression 1385 
behavioural symptoms at age 19 (r =0.19(180), p = 0.003, 95% CIs=0.069,∞), but not at age 14 1386 
(r=0.020(180), p=0.40, 95% CIs=-0.10,∞). Brain correlates at 14 years predict the manifestation of 1387 
behavioral symptoms at 19 years (r=0.14(180), p=0.023, 95% CIs=0.022,∞). (b) Executive 1388 
dysfunction symptom correlates: VBM and TBSS correlates established at age 19 are associated with 1389 
behavioral symptoms at age 19 (r =0.15(180), p = 0.024, 95% CIs=0.028,∞), but not at age 14 1390 
(r=0.030(180), p=0.41, 95% CIs=-0.093,∞). Brain correlates at 14 years do not predict the 1391 
manifestation of behavioral symptoms at 19 years (r=0.11(180), p=0.065, 95% CIs =-0.010,∞).   1392 
 1393 
 1394 
Figure 4: Differences in the grey matter correlates of anxiety/depression and executive dysfunction 1395 
psychiatric symptoms, between cases and controls for a range of psychiatric illnesses. For the box 1396 
and whisker plots, the central mark in each box represents the median, with the top and bottom edges 1397 
of the box indicating the 25th and 75th percentiles of the sample respectively, whiskers represent 1.5x 1398 
the interquartile range and the hollow circles represent sample outliers. For display purposes, total 1399 
grey matter in each case-control comparison is divided by the pooled standard deviation.  The effect 1400 
sizes (calculated using Cohen’s D) relating to these differences are shown in the right-hand panel. (a): 1401 
Differences in grey matter volume between patients and controls in the anxiety/depression set of grey 1402 
matter correlates are shown in the left-hand panel.  Clinical psychiatric disorders exhibited the 1403 
following case-control differences: Depression: t-statistic=4.61(612), p<0.001, Cohen’s D = 0.39, 95% 1404 
CIs=0.25, ∞; Schizophrenia: t-statistic=2.54(445), p=0.002, Cohen’s D=0.25, 95% CIs = 0.087, ∞; 1405 
ADHD (t-statistic=1.84(203), p=0.034, Cohen’s D=0.26, 95% CIs=0.030, ∞;  Bipolar: (t-statistic=-1406 
0.23(473), p=0.59, Cohen’s D=-0.02, 95% CIs=-0.17, ∞). (b): Differences in grey matter volume 1407 
between patients and controls in the executive dysfunction set of grey matter correlates. Clinical 1408 
psychiatric disorders exhibited the following case-control differences: Depression: t-1409 
statistic=1.65(612), p=0.050, Cohen’s D=0.14, 95% CIs=0.001, ∞, Schizophrenia:  t-1410 
statistic=2.81(445), p=0.0026, Cohen’s D=0.28, 95% CIs=0.11, ∞; ADHD: t-statistic=2.19(203), 1411 
p=0.014, Cohen’s D=0.32, 95% CIs=0.070, ∞; Bipolar: t-statistic=-1.33(473), p=0.90, Cohen’s D=-1412 
0.12, 95% CIs=-0.27, ∞. 1413 
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